spacer
home > pmps > winter 2018 > dose counters & indicators: a real patient need
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Dose Counters & Indicators: A Real Patient Need

Asthma and chronic obstructive pulmonary disease (COPD) are chronic lung disorders responsible for millions of deaths every year. Both diseases are characterised by variable and recurring symptoms and, when poorly controlled, can result in severe limitations in quality of life of patients. Therefore, controlling and monitoring treatments is not only a real need to reduce healthcare costs related to hospitalisations, but a real patient need. Patient expectations are towards a reliable system to support their correct and on-time use of inhalers, without changing the way of using them or adding any steps to their routine: intuitive and non-destructive, without much additional weight or form, factor into transporting them in their daily lives.

The majority of marketed metereddose inhalers (MDIs) offer no practical way for patients or doctors to know how many doses are left in their inhaler, specifically in case of emergency. Furthermore, there is a collective requirement to track adherence or compliance to medication. To address these requirements, the FDA published guidance on integration of dosecounting mechanisms into MDI drug products. Under this guidance, devices should offer either clear numeric counting mechanisms or indication functions with colour coding or other means, leading to clear and unmistakable information to patients on the quantity of the drug left in their devices (1,2). The guidance also encourages drug manufacturers to update existing devices, if possible.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Presspart Manufacturing
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

E Ink and Faubel Unveil the Med Label to Revolutionize the Clinical Trial Supply Chain

E Ink® Holdings, "E Ink" (8069.TW), the leading innovator of electronic ink technology and Faubel & Co. Nachf. GmbH, a proven supplier to the pharmaceutical and chemical industry, announced the availability of the Faubel-Med® Label, a smart label for investigational medicinal products. The Med Label features E Ink’s low-voltage film technology, bringing display modules and new system designs to pharmaceutical packaging.
More info >>

White Papers

Achieve full compliance with tamper-verification pharma solutions

UPM Raflatac

UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >>

 
Industry Events

Cell Line Development and Engineering

23-25 April 2018, RAI, Amsterdam

Cell Line Development & Engineering 2018 event will be held 23-25 April 2018 in the RAI Amsterdam – joining the largest Bioprocessing event in Europe – BPI Europe.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement